ONLINE SEMINAR RECORDING – MARCH 25, 2021
ONLINE SEMINAR RECORDING – MARCH 25, 2021
Learn more about BCL6 Degrader | BI-3802 Discover now
Agenda
| Part 1 | The discovery of BI-3802 as a potent and selective degrader of transcription factor BCL6 | Manfred Koegl Steffen Steurer |
| Part 2 | BI-3802 involves a new mechanism of targeted protein degradation | Mikołaj Słabicki Hojong Yoon Jonas Koeppel |
| Part 3 | Discussion and Q&A | Please join with your questions |
What is the context of this online seminar?
BCL6 degrader BI-3802 is a single digit nanomolar BCL6::Co-repressor inhibitor which induces efficacious BCL6 protein degradation and represents an ideal in vitro probe compound for testing hypotheses around BCL6 biology. The molecule is made available on opnMe.com free of charge to foster independent innovation of scientific groups. As part of the seminar, we will introduce its initial characterization through scientists at Boehringer Ingelheim. We will then highlight recent findings1 of a team at Dana Farber Institute / Broad Institute who unveiled its unique mode of action after having obtained the molecule via opnMe.com. These insights may open new avenues for the development of therapeutic agents and synthetic biology.
1Small-molecule-induced polymerization triggers degradation of BCL6 Słabicki M., Yoon H., Koeppel J., Nitsch L., Roy Burman S. S., Di Genua C., Donovan K. A., Sperling A. S., Hunkeler M., Tsai J. M., Sharma R., Guirguis A., Zou C., Chudasama P., Gasser J. A., Miller P. G., Scholl C., Fröhling S., Nowak R. P., Fischer E. S., Ebert B. L. Nature 2020, 588, 164–168.